Urologic oncology
Journal
Overview
publication venue for
-
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
2022
-
Patient preferences for life expectancy cutoffs for aggressive treatment in clinically localized prostate cancer.
2024
-
Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions.
2024
-
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy.
2024
-
Long-term outcomes of pelvic-fascia sparing robotic-assisted radical prostatectomy versus standard technique: Superior urinary function and quality of life without compromising oncologic efficacy in a single-surgeon series.
2024
-
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer..
41.
2023
-
Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites.
2023
-
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma..
41.
2023
-
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
2023
-
Conditional survival of stage III non-seminoma testis cancer patients..
41.
2023
-
Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy..
41.
2023
-
Insurer coverage of prostate cancer biomarkers.
2023
-
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma..
41.
2023
-
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer..
41.
2023
-
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder..
41.
2022
-
Collecting duct carcinoma: Epidemiology, clinical characteristics and survival..
41.
2022
-
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis..
41.
2022
-
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy..
41.
2022
-
Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity..
40.
2022
-
Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma..
40.
2022
-
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer..
40.
2022
-
Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core..
40.
2022
-
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer..
40.
2022
-
A multidisciplinary approach to optimize primary prostate cancer biobanking.
2022
-
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity..
40.
2022
-
Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists..
40.
2022
-
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?
2022
-
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.
2022
-
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients..
40.
2021
-
Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy..
40.
2021
-
Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.
2021
-
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?.
40.
2021
-
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma..
39.
2021
-
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis..
39.
2021
-
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder..
40.
2021
-
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma..
39.
2021
-
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02..
40.
2021
-
Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer..
39.
2021
-
Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study..
39.
2021
-
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients..
39.
2021
-
Prognostic significance of histomorphologic features of lymph node metastases in prostate cancer patients treated with radical prostatectomy: A single center study..
39.
2021
-
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer..
39.
2021
-
Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study..
39.
2021
-
Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer..
39.
2021
-
Tumor size and genomic risk in localized prostate cancer..
39.
2021
-
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study..
39.
2021
-
Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup..
39.
2020
-
The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer..
39.
2020
-
Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?.
39.
2020
-
A population-level analysis of nonsquamous penile cancer: The importance of histology..
39.
2020
-
The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy..
39.
2020
-
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab..
39.
2020
-
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy..
39.
2020
-
The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis..
39.
2020
-
Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma..
38.
2020
-
Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey..
39.
2020
-
Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort..
38.
2020
-
Primary Ta high grade bladder tumors: Determination of the risk of progression..
39.
2020
-
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size..
38.
2020
-
Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?.
38.
2020
-
Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer..
39.
2020
-
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival..
38.
2020
-
Bladder cancer incidence rates and trends in young adults aged 20-39 years..
38.
2020
-
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer..
38.
2020
-
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer..
39.
2020
-
The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort..
38.
2020
-
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy..
38.
2020
-
Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions..
38.
2020
-
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)..
38.
2020
-
Prognostic value of the SPOP mutant genomic subclass in prostate cancer..
38.
2020
-
Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis..
38.
2020
-
Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma..
38.
2020
-
Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy..
38.
2020
-
Histomorphological analysis of false positive PI-RADS 4 and 5 lesions..
38.
2020
-
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer..
38.
2020
-
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration..
38.
2020
-
Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients..
38.
2020
-
PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy..
38.
2019
-
Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer..
38.
2019
-
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?.
38.
2019
-
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy..
38.
2019
-
The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma..
37.
2019
-
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?.
38.
2019
-
Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma..
37.
2019
-
Definitive and sustained increase in prostate cancer metastases in the United States..
37.
2019
-
Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates..
37.
2019
-
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder..
37.
2019
-
Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer..
37.
2019
-
A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study)..
37.
2019
-
Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study..
37.
2019
-
Perioperative, oncological and functional outcomes after robotic partial nephrectomy vs. cryoablation in the elderly: A propensity score matched analysis..
37.
2019
-
National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer..
37.
2019
-
Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer..
36.
2019
-
Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer..
37.
2018
-
Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder..
37.
2018
-
Role of serum cholinesterase in patients treated with salvage radical prostatectomy..
37.
2018
-
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy..
37.
2018
-
Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy..
36.
2018
-
A urinary microRNA (miR) signature for diagnosis of bladder cancer..
36.
2018
-
Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes..
36.
2018
-
An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States..
36.
2018
-
Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma..
36.
2018
-
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance..
36.
2018
-
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer..
36.
2018
-
Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy..
36.
2018
-
Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool..
36.
2018
-
Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer..
36.
2018
-
Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer..
36.
2017
-
Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification..
36.
2017
-
Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C..
36.
2017
-
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations..
37.
2017
-
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)..
36.
2017
-
Concordance between patient-reported and physician-reported sexual function after radical prostatectomy..
36.
2017
-
Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database..
36.
2017
-
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes..
36.
2017
-
Predictors of genitourinary malignancy in patients with asymptomatic microscopic hematuria..
36.
2017
-
Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer..
36.
2017
-
Population-based study of the incidence and survival for intraductal carcinoma of the prostate..
35.
2017
-
The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma..
35.
2017
-
Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy..
35.
2017
-
Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis..
35.
2017
-
Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?.
35.
2017
-
Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database..
35.
2017
-
Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study..
35.
2017
-
Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study..
35.
2017
-
Regionalization of radical cystectomy in the United States..
35.
2017
-
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer..
35.
2017
-
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy..
35.
2017
-
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma..
35.
2017
-
Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer..
35.
2017
-
Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer..
35.
2017
-
Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy..
35.
2017
-
Health status and use of partial nephrectomy in older adults with early-stage kidney cancer..
35.
2016
-
Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma..
35.
2016
-
The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes..
35.
2016
-
Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer..
35.
2016
-
External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study..
35.
2016
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer..
34.
2016
-
Technique and outcomes of bladder neck intussusception during robot-assisted laparoscopic prostatectomy: A parallel comparative trial..
34.
2016
-
Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer..
34.
2016
-
The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer..
34.
2016
-
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer..
34.
2016
-
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer..
34.
2016
-
Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer..
34.
2016
-
The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models..
35.
2016
-
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis..
34.
2016
-
Determinants of radical cystectomy operative time..
34.
2016
-
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?.
34.
2016
-
GATA3 immunohistochemical expression in invasive urothelial carcinoma..
34.
2016
-
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy..
34.
2016
-
Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution..
34.
2016
-
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm..
34.
2016
-
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes..
34.
2015
-
Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial..
34.
2015
-
Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups..
34.
2015
-
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity..
34.
2015
-
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design..
33.
2015
-
Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study..
33.
2015
-
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools..
33.
2015
-
Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation..
33.
2015
-
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging..
33.
2015
-
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study..
33.
2015
-
The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry..
33.
2015
-
Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?.
33.
2014
-
The burden of skeletal-related events in patients with prostate cancer and bone metastasis..
33.
2014
-
Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model..
33.
2014
-
The association between nerve sparing and a positive surgical margin during radical prostatectomy..
33.
2014
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)..
32.
2014
-
The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma..
33.
2014
-
Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort..
33.
2014
-
Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer..
32.
2014
-
Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly..
33.
2014
-
Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness..
32.
2014
-
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis..
32.
2014
-
Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy..
32.
2014
-
Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer..
32.
2014
-
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States..
32.
2014
-
The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder..
32.
2014
-
Prognostic effect of serum and tissue YKL-40 levels in bladder cancer..
32.
2014
-
Minimal changes in the systemic immune response after nephrectomy of localized renal masses..
32.
2014
-
Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy..
32.
2014
-
Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder..
32.
2014
-
Local tumor destruction in renal cell carcinoma--an inpatient population-based study..
32.
2014
-
Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature..
32.
2014
-
Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer..
32.
2013
-
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma..
32.
2013
-
High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy..
32.
2013
-
Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?.
32.
2013
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance..
32.
2013
-
The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy..
32.
2013
-
Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models..
32.
2013
-
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death..
32.
2013
-
Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?.
32.
2013
-
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy..
31.
2012
-
Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America..
31.
2012
-
Morbidity and costs of salvage vs. primary radical prostatectomy in older men..
31.
2012
-
Discharge patterns after radical prostatectomy in the United States of America..
31.
2011
-
Comprehensive handbook for developing a bladder cancer cystectomy database..
31.
2011
-
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma..
31.
2011
-
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer..
31.
2011
-
Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells..
31.
2011
-
Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy..
31.
2011
-
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer..
31.
2011
-
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder..
31.
2011
-
RET protein expression in papillary renal cell carcinoma..
30.
2011
-
Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma..
30.
2010
-
The effect of minimally invasive and open radical prostatectomy surgeon volume..
30.
2010
-
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer..
29.
2010
-
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy..
30.
2010
-
Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?.
29.
2010
-
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer..
28.
2010
-
What is the optimal management of high risk, clinically localized prostate cancer?.
28.
2010
-
The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy..
29.
2009
-
Critical elements in fellowship training..
27.
2009
-
Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?.
29.
2008
-
Impact of radical prostatectomy positive surgical margins on fear of cancer recurrence: results from CaPSURE..
28.
2008
-
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model..
27.
2008
-
A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate..
27.
2008
-
Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder..
25.
2007
-
Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts..
25.
2007
-
Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial..
23.
2005
-
Medical care cost of patients with prostate cancer..
23.
2005
-
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors..
21.
2003
-
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men..
7.
2002
-
Mode of presentation of renal cell carcinoma provides prognostic information..
7.
2002
-
Cytokine therapy in renal cell cancer..
5.
2000
-
Timing of cystectomy for superficial bladder tumors..
5.
2000
-
Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management..
5.
2000
-
Updated concepts and treatment of carcinoma in situ..
4.
1998
-
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate..
4.
1998
-
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer..
3.
1997
-
Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy..
2.
1996
-
Selecting clinical research projects for the urologic oncologist..
2.
1996
-
Uncertainty and outcome of invasive bladder tumors..
2.
1996
-
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder..
1.
1995
-
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4)..
33.
2015
-
Segmental ureterectomy for upper tract urothelial carcinoma: two procedures with different indications..
31.
2013
-
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?.
29.
2010
-
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al.
2020
-
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy..
33.
2015
-
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval..
33.
2015
-
Training of a surgeon-scientist..
27.
2009
-
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies..
27.
2009
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.
2021
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer.
2021
-
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges.
2021
-
Systemic therapy in bladder preservation.
2020
-
Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis.
2020
-
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.
2019
-
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.
2019
-
Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.
2019
-
Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy".
2018
-
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
2018
-
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer.
2018
-
Novel biomarkers in bladder cancer.
2018
-
A multidisciplinary approach for the management of earlier stage renal cell carcinoma.
2018
-
Prostate cancer risk stratification with magnetic resonance imaging.
2016
-
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
2016
-
Immunotherapy for genitourinary malignancies in the here and now!
2015
-
Pediatric and adolescent renal cell carcinoma.
2015
-
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
2015
-
Salvage high-dose chemotherapy for germ cell tumors.
2015
-
Enzalutamide: Development from bench to bedside.
2015
-
Biomarkers for immunotherapy in genitourinary malignancies.
2015
-
Biomarker development in the context of urologic cancers.
2015
-
Reprint of: The prostate cancer genome: Perspectives and potential.
2015
-
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
2014
-
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.
2014
-
Prostate cancer biomarkers: an update.
2014
-
Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy.
2013
-
The prostate cancer genome: perspectives and potential.
2013
-
Urine markers for detection and surveillance of bladder cancer.
2013
-
Current status of focal primary therapy for prostate cancer.
2012
-
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.
2012
-
Prostate-specific membrane antigen-based imaging.
2012
-
Environmental toxicology of testicular cancer.
2012
-
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
2012
-
Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
2012
-
Statistical consideration for clinical biomarker research in bladder cancer.
2010
-
Optimal timing of radical cystectomy for patients with T1 bladder cancer.
2009
-
Optimizing outcomes at every stage of bladder cancer: do we practice it?
2009
-
Laparoscopic radical prostatectomy: contemporary comparison with open surgery.
2007
-
Low risk prostate cancer in men under age 65: the case for definitive treatment.
2007
-
The use and abuse of data: nomograms and talking to patients about clinical medicine.
2007
-
A new era in the treatment of urothelial carcinoma.
2023
-
Antibody-drug conjugates for urothelial carcinoma.
2023
-
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
2023
-
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
2023
-
Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy.
2022
-
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
2022
-
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis.
2022
-
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
2022
-
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints.
2021
-
Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
2021
-
Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
2021
-
Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.
2021
-
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
2021
-
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
2021
-
The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis.
2020
-
Inguinal lymph node dissection in the era of minimally invasive surgical technology.
2020
-
Role of lymph node dissection in renal cell cancer.
2019
-
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
2017
-
Heterogeneity in renal cell carcinoma.
2017
-
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.
2016
-
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
2015
-
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice.
2014
-
Highlights from the first symposium on upper tract urothelial carcinoma.
2014
-
Radical prostatectomy: positive surgical margins matter.
2012
-
Salvage therapies after radiation therapy.
2012
-
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
2010
-
Bladder cancer in the elderly.
2009
-
Do high-volume hospitals and surgeons provide better care in urologic oncology?
2009
-
Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
2008
-
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
2006
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)